JOP20190273A1 - مركب إنسولين معالج بأسيل - Google Patents
مركب إنسولين معالج بأسيلInfo
- Publication number
- JOP20190273A1 JOP20190273A1 JOP/2019/0273A JOP20190273A JOP20190273A1 JO P20190273 A1 JOP20190273 A1 JO P20190273A1 JO P20190273 A JOP20190273 A JO P20190273A JO P20190273 A1 JOP20190273 A1 JO P20190273A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- acylated insulin
- insulin compound
- relate
- acylated
- Prior art date
Links
- -1 Acylated insulin compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
تتعلق المركبات الموصوفة حاليًا بعلاج داء السكري و/أو فرط السكر بالدم. على نحو أكثر تحديدًا، تتعلق المركبات الموصوفة بمركبات إنسولين معالجة بأسيل تقلل جلوكوز الدم، تركيبات صيدلية تحتوي على هذه المركبات، الاستخدامات العلاجية لهذه المركبات، ومركب وسيط يستخدم لتصنيع مركبات الإنسولين المعالجة بأسيل.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511690P | 2017-05-26 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190273A1 true JOP20190273A1 (ar) | 2019-11-24 |
Family
ID=62528889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0273A JOP20190273A1 (ar) | 2017-05-26 | 2017-06-16 | مركب إنسولين معالج بأسيل |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10400021B2 (ar) |
| EP (1) | EP3630165A1 (ar) |
| JP (1) | JP6665349B2 (ar) |
| KR (1) | KR102271057B1 (ar) |
| CN (1) | CN110691608B (ar) |
| AR (1) | AR112353A1 (ar) |
| AU (1) | AU2018273777B2 (ar) |
| BR (1) | BR112019021668A2 (ar) |
| CA (1) | CA3065078C (ar) |
| CL (1) | CL2019003259A1 (ar) |
| CO (1) | CO2019012964A2 (ar) |
| CR (1) | CR20190523A (ar) |
| DO (1) | DOP2019000296A (ar) |
| EA (1) | EA038073B1 (ar) |
| EC (1) | ECSP19083930A (ar) |
| IL (1) | IL270813B1 (ar) |
| JO (1) | JOP20190273A1 (ar) |
| MA (1) | MA49310A (ar) |
| MX (1) | MX2019014086A (ar) |
| PE (1) | PE20191836A1 (ar) |
| PH (1) | PH12019502655A1 (ar) |
| SA (1) | SA519410448B1 (ar) |
| TW (1) | TWI672315B (ar) |
| WO (1) | WO2018217573A1 (ar) |
| ZA (1) | ZA201906955B (ar) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019398579A1 (en) | 2018-12-11 | 2021-07-29 | Sanofi | Peptide binder |
| TW202120536A (zh) | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| KR20220121833A (ko) * | 2019-12-30 | 2022-09-01 | 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 | 인슐린 유도체 |
| KR20230009499A (ko) * | 2020-05-15 | 2023-01-17 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용 아실화된 인슐린 화합물 |
| WO2023225534A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
| WO2024051787A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2306877A1 (en) * | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Insoluble insulin compositions |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| PL2107069T3 (pl) | 2003-08-05 | 2013-06-28 | Novo Nordisk As | Nowe pochodne insuliny |
| EP2292653B1 (en) | 2005-02-02 | 2014-05-21 | Novo Nordisk A/S | Novel insulin derivatives |
| KR20100053561A (ko) * | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| US8962794B2 (en) * | 2007-08-15 | 2015-02-24 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| EP2910569B1 (en) * | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| CN102256992B (zh) * | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
| JP6755175B2 (ja) | 2013-03-20 | 2020-09-16 | ノヴォ ノルディスク アー／エス | インスリン投薬レジメン |
| EP2991672A1 (en) * | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
-
2017
- 2017-06-16 JO JOP/2019/0273A patent/JOP20190273A1/ar unknown
-
2018
- 2018-05-11 AR ARP180101254 patent/AR112353A1/es unknown
- 2018-05-11 TW TW107116025A patent/TWI672315B/zh active
- 2018-05-18 KR KR1020197034368A patent/KR102271057B1/ko active Search and Examination
- 2018-05-18 PE PE2019002403A patent/PE20191836A1/es unknown
- 2018-05-18 CN CN201880034670.1A patent/CN110691608B/zh active Active
- 2018-05-18 MA MA049310A patent/MA49310A/fr unknown
- 2018-05-18 US US15/983,167 patent/US10400021B2/en active Active
- 2018-05-18 CR CR20190523A patent/CR20190523A/es unknown
- 2018-05-18 CA CA3065078A patent/CA3065078C/en active Active
- 2018-05-18 EP EP18729289.1A patent/EP3630165A1/en active Pending
- 2018-05-18 IL IL270813A patent/IL270813B1/en unknown
- 2018-05-18 EA EA201992272A patent/EA038073B1/ru unknown
- 2018-05-18 BR BR112019021668-5A patent/BR112019021668A2/pt unknown
- 2018-05-18 WO PCT/US2018/033418 patent/WO2018217573A1/en active Application Filing
- 2018-05-18 JP JP2019520536A patent/JP6665349B2/ja active Active
- 2018-05-18 AU AU2018273777A patent/AU2018273777B2/en active Active
- 2018-05-18 MX MX2019014086A patent/MX2019014086A/es active IP Right Grant
-
2019
- 2019-08-01 US US16/529,095 patent/US10597436B2/en active Active
- 2019-10-22 ZA ZA2019/06955A patent/ZA201906955B/en unknown
- 2019-10-31 SA SA519410448A patent/SA519410448B1/ar unknown
- 2019-11-14 CL CL2019003259A patent/CL2019003259A1/es unknown
- 2019-11-19 CO CONC2019/0012964A patent/CO2019012964A2/es unknown
- 2019-11-22 DO DO2019000296A patent/DOP2019000296A/es unknown
- 2019-11-25 PH PH12019502655A patent/PH12019502655A1/en unknown
- 2019-11-25 EC ECSENADI201983930A patent/ECSP19083930A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502655A1 (en) | Acylated insulin compound | |
| JOP20210201A1 (ar) | مركب لخفض جلوكوز الدم | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| MX368387B (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| MX2019007119A (es) | Preparado oral del activador de glucocinasa y preparacion del mismo. | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| PH12019501363A1 (en) | Insulin containing pharmaceutical compositions | |
| MX2019007641A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| MX2022014309A (es) | Compuestos de insulina acilada de accion temporal prolongada. | |
| PH12017501486A1 (en) | Nasal powder formulation for treatment of hypoglycemia | |
| EA201201617A1 (ru) | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы | |
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
| MX2020014262A (es) | Composicion farmaceutica que comprende un agente basico poco soluble. | |
| WO2016126026A3 (ko) | 당뇨병 치료 조성물 및 이의 용도 | |
| WO2020018058A3 (en) | The injectable micronized human insulin | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
| PL413779A1 (pl) | Zastosowanie medyczne 4-cykloheksylo-1-(4-nitrofenylo)-karbonylotiosemikarbazydu oraz kompozycja farmaceutyczna | |
| MX2016001357A (es) | Compuestos de ciclobutilo 1,2-disustituidos. |